Form 4: Guardant Health Director Exercises Options, Sells Shares
Insider Transaction Report
Guardant Health Director Ian T. Clark exercised stock options and subsequently sold a portion of his indirectly held common stock on December 5, 2025, under a Rule 10b5-1 plan.
Summary
- Director Ian T. Clark, through The Thornton-Clark Family Trust, acquired a total of 28,611 shares of Guardant Health common stock by exercising three tranches of stock options on December 5, 2025.
- The option exercise prices were $38.42 for 9,105 shares, $38.005 for 8,803 shares, and $31.84 for 10,703 shares.
- Concurrently, 28,611 shares of common stock were sold in three separate transactions on December 5, 2025.
- The sales occurred at weighted average prices of $106.666 for 8,156 shares, $107.2703 for 17,055 shares, and $108.0454 for 3,400 shares.
- All transactions were executed pursuant to a Rule 10b5-1 plan.
- Following these transactions, the indirect beneficial ownership of common stock by The Thornton-Clark Family Trust stands at 9,851 shares.
Sentiment
Score: 5
Explanation: The filing reports a director's exercise of stock options and subsequent sale of shares, which is a common event for insider compensation and liquidity management, especially when executed under a Rule 10b5-1 plan. This is a routine transaction and does not inherently indicate a positive or negative sentiment about the company's future.
Positives
- The director exercised stock options, indicating that the options were in-the-money and provided a significant gain.
- The sales were executed at prices substantially higher than the option exercise prices, demonstrating a profitable transaction for the insider.
Negatives
- Insider selling, even under a pre-arranged plan, can sometimes be perceived by the market as a reduction in direct exposure to the company's equity.
Related Party Transactions
- Director Ian T. Clark's transactions were conducted indirectly through The Thornton-Clark Family Trust, where J Thornton-Clark and I Clark serve as trustees.
Stakeholder Impact
- Shareholders may observe a reduction in the director's indirect equity holdings, which is a common occurrence for liquidity or diversification purposes, particularly when pre-scheduled under a Rule 10b5-1 plan.
Key Dates
| Date | Description |
|---|---|
| 06/15/2022 | Grant date for 9,105 stock options with an exercise price of $38.42. |
| 06/14/2023 | Grant date for 8,803 stock options with an exercise price of $38.005. |
| 06/12/2024 | Grant date for 10,703 stock options with an exercise price of $31.84. |
| 12/05/2025 | Date of all reported transactions, including option exercises and subsequent sales of common stock. |
| 12/08/2025 | Signature date of the Form 4 filing. |
| 06/15/2032 | Expiration date for 9,105 stock options. |
| 06/14/2033 | Expiration date for 8,803 stock options. |
| 06/12/2034 | Expiration date for 10,703 stock options. |
Recommendation
holdThe filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares by a director under a pre-arranged Rule 10b5-1 plan. Such transactions are common for liquidity and compensation purposes and do not typically signal a fundamental change in the company's outlook or warrant a change in investment recommendation based solely on this report.
Keywords
Guardant Health, GH, Insider Trading, Form 4, Stock Options, Director, Share Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.